


IN THE CLAIMS:

Please amend claims 41, 42 and 46, without prejudice, as follows:

Claims 1-40 (cancelled).

Claim 41 (currently amended): A method of treating inhibiting-HIV replication-infection in a mammal, wherein said HIV infection is modulated by a CCR5 receptor in said mammal, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof:



wherein R¹ is C₃₋₆ cycloalkyl optionally substituted by one or more fluorine atoms, or C₁₋₆ alkyl optionally substituted by one or more fluorine atoms, or C₃₋₆ cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and

R² is phenyl optionally substituted by one or more fluorine atoms.

Claim 42 (currently amended): A method of treating inhibiting-HIV replication-infection in a mammal, wherein said HIV infection is modulated by a CCR5 receptor in said mammal, comprising administering to said mammal an effective amount of a compound selected from the group consisting of:

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)cyclobutanecarboxamide;

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)cyclopentanecarboxamide;

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)-4,4,4-trifluorobutanamide;

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)-4,4-difluorocyclohexanecarboxamide; and

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-(3-fluorophenyl)propyl)-4,4-difluorocyclohexanecarboxamide;

or a pharmaceutically acceptable salt or solvate thereof.

Claims 43-45 (Cancelled).

Claim 46 (currently amended): A method of treating inhibiting-HIV replication-infection in a mammal, wherein said HIV infection is modulated by a CCR5 receptor in said mammal, comprising administering to said mammal an effective amount of N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)-4,4-difluorocyclohexanecarboxamide or a pharmaceutically acceptable salt or solvate thereof.